Elucidation of a human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy

Fitzgerald, Bryna L. ; Islam, M. Nurul ; Graham, Barbara ; Mahapatra, Sebabrata ; Webb, Kristofor ; Boom, W. Henry ; Malherbe, Stephanus T. ; Joloba, Moses L. ; Johnson, John L. ; Winter, Jill ; Walzl, Gerhard ; Belisle, John T. (2018-12-26)

CITATION: Fitzgerald, B. L., et al. 2019. Elucidation of a human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy. ACS Infectious Diseases, 5(3):353-364, doi:10.1021/acsinfecdis.8b00241.

The original publication is available at https://pubs.acs.org

Article

ENGLISH ABSTRACT: The evaluation of new tuberculosis (TB) therapies is limited by the paucity of biomarkers to monitor treatment response. Previous work detected an uncharacterized urine metabolite with a molecular mass of 874.3547 Da that showed promise as a biomarker for successful TB treatment. Using mass spectrometry combined with enzymatic digestions, the metabolite was structurally characterized as a seryl-leucine core 1 Oglycosylated peptide (SLC1G) of human origin. Examination of SLC1G in urine revealed a significant abundance increase in individuals with active TB versus their household contacts and healthy controls. Moreover, differential decreases in SLC1G levels were observed by week one in TB patients during successful treatment versus those that failed treatment. The SLC1G levels were also associated with clinical parameters used to measure bacterial burden (GeneXpert) and inflammation (positron emission tomography-computed tomography (PET-CT)). These results demonstrate the importance of metabolite identification and provide strong evidence for applying SLC1G as a biomarker of TB treatment response.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/108996
This item appears in the following collections: